After few pipeline failures in the research pipelines of the company, Celgene is all set to launch five innovative molecules from present to the end of 2020. The company’s top selling drug Revlimid, is expected to face a major patent cliff by 2020. If the generic drug manufacturing companies are successful in developing the generic version of Revlimid, the company is likely to witness a major loss in its revenue.
Therefore, to overcome this dependency on Revlimid, the company is all set to file its potential blockbusters products for regulatory approval. These pipeline products are ozanimod for multiple sclerosis therapy, fedratinib for the treatment of myelofibrosis, luspatercept for thalassaemia, and lymphoma therapy lisocabtagene maraleucel (liso-cel) and multiple myeloma therapy bb2121. Lisocabtagene maraleucel and bb2121 are the potential CAR-T candidates of the company, which is anticipated to be approved in 2020, while the other three candidates are due to be submitted from the end of this year through the first half of 2019. The new results for both CAR-T therapies are expected to be launched in the American Society of Haematology (ASH) meeting in December.
Celgene is also making efforts to extend the use of its Otezla drug with added indications, and in spite of varied data of phase 2 trials for ulcerative colitis, the company has moved forward with a registering this indication in Crohn’s disease.
The quarterly statistics has showed that Revlimid has 18% gain, Pomalyst (pomalidomide) revenue increased by 23% and Otezla gained 40% boost, which has strengthened the company’s position in the market.
– Rikitha K Murthy,